Regardless of the FDA's decision, NPS also has a solid royalty stream that's earned it $60 million through the first six months of this year, including $55 million paid to it by Amgen ( AMGN 1.21% ) for Sensipar, which was approved in 2004 for hypoparathyroidism. Thanks to sales of Gattex and royalties, NPS Pharma is slated to produce EPS of $0.02 this year and $1.15 next year. If it can deliver on that EPS growth, investors may find that shares head higher.